Sagent Pharmaceuticals (SGNT) Shares are Down -0.5%

Sagent Pharmaceuticals (SGNT) has risen sharply, recording gains of 44.41% in the past 4 weeks. However, the stock has corrected -0.5% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 35.27% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Sagent Pharmaceuticals (NASDAQ:SGNT): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $21.70 and $21.65 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $21.72. The buying momentum continued till the end and the stock did not give up its gains. It closed at $21.69, notching a gain of 0.09% for the day. The total traded volume was 848,178 . The stock had closed at $21.67 on the previous day.


The stock has recorded a 20-day Moving Average of 19.81% and the 50-Day Moving Average is 43.88%. Sagent Pharmaceuticals, Inc. is up 68.93% in the last 3-month period. Year-to-Date the stock performance stands at 36.33%.

Sagent Pharmaceuticals, Inc. (Sagent), formerly Sagent Holding Co., is an injectable pharmaceutical company that develops and sources products that the Company sells primarily in the United States. Sagent focuses primarily on generic injectable pharmaceuticals. Sagent offers its customers a range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled, ready-to-use syringes, medical devices and premix bags. As of October 31, 2010, Sagent marketed 21 products. The Company has a 50/50 joint venture known as Sagent Strides LLC (Sagent Strides) with a subsidiary of Strides Arcolab Limited (Strides), which is an Indian manufacturer of finished pharmaceutical products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.